TY - JOUR
T1 - Neoadjuvant Chemotherapy Improves Oncological Outcomes and Long-Term Survival Among Elderly Patients with Locally Advanced Gastric Cancer
T2 - A Propensity Score Matched Analysis
AU - Rawicz-Pruszyński, Karol
AU - Endo, Yutaka
AU - Tsilimigras, Diamantis I.
AU - Munir, Muhammad Musaab
AU - Resende, Vivian
AU - Kim, Alex
AU - Beane, Joal
AU - Pelc, Zuzanna
AU - Sędłak, Katarzyna
AU - Pawlik, Timothy M.
N1 - Publisher Copyright:
© 2023, Society of Surgical Oncology.
PY - 2024/2
Y1 - 2024/2
N2 - Introduction: In the USA, approximately half of newly diagnosed patients with GC are 75 years or older. The objective of the current population-based study was to investigate the impact of neoadjuvant chemotherapy (NAC) on the outcomes of elderly patients with locally advanced GC. Patients and Methods: Patients aged > 75 years were identified from the National Cancer Database (NCDB). The primary outcome of the study was overall survival (OS). Secondary outcomes included lymph node (LN) harvest, surgical margin status, and 30-day mortality. To minimize the effect of selection bias on the assessed outcome between the two study groups (NAC versus no NAC), propensity score matching (PSM) was performed. Results: After PSM, a total of 1958 patients were included in both groups. NAC utilization increased from 2013 to 2019 (21% versus 42.7%, p trend < 0.001). On pathologic analysis, patients who received NAC were more likely to have ≥ 16 LNs evaluated (NAC 60.1% versus no NAC 55.5%, p = 0.044) and negative resection margins (NAC 88.6% versus no NAC 83%, p = 0.001). Patients who received NAC were also less likely to experience 30-day mortality following resection (NAC 4.1% versus no NAC 7.1%). Receipt of NAC was associated with improved 1-year (73.9% versus 68.3%), 3-year (48.2% versus 43.5%), and 5-year OS (36.9% versus 30.5%) compared with patients who underwent upfront surgery (p = 0.01). Conclusions: Receipt of NAC was associated with improved oncological outcomes among elderly patients undergoing resection for locally advanced GC.
AB - Introduction: In the USA, approximately half of newly diagnosed patients with GC are 75 years or older. The objective of the current population-based study was to investigate the impact of neoadjuvant chemotherapy (NAC) on the outcomes of elderly patients with locally advanced GC. Patients and Methods: Patients aged > 75 years were identified from the National Cancer Database (NCDB). The primary outcome of the study was overall survival (OS). Secondary outcomes included lymph node (LN) harvest, surgical margin status, and 30-day mortality. To minimize the effect of selection bias on the assessed outcome between the two study groups (NAC versus no NAC), propensity score matching (PSM) was performed. Results: After PSM, a total of 1958 patients were included in both groups. NAC utilization increased from 2013 to 2019 (21% versus 42.7%, p trend < 0.001). On pathologic analysis, patients who received NAC were more likely to have ≥ 16 LNs evaluated (NAC 60.1% versus no NAC 55.5%, p = 0.044) and negative resection margins (NAC 88.6% versus no NAC 83%, p = 0.001). Patients who received NAC were also less likely to experience 30-day mortality following resection (NAC 4.1% versus no NAC 7.1%). Receipt of NAC was associated with improved 1-year (73.9% versus 68.3%), 3-year (48.2% versus 43.5%), and 5-year OS (36.9% versus 30.5%) compared with patients who underwent upfront surgery (p = 0.01). Conclusions: Receipt of NAC was associated with improved oncological outcomes among elderly patients undergoing resection for locally advanced GC.
KW - Elderly
KW - Gastric cancer
KW - Multimodal treatment
KW - Neoadjuvant chemotherapy
KW - Upfront surgery
UR - http://www.scopus.com/inward/record.url?scp=85176770907&partnerID=8YFLogxK
U2 - 10.1245/s10434-023-14569-y
DO - 10.1245/s10434-023-14569-y
M3 - Article
C2 - 37985525
AN - SCOPUS:85176770907
SN - 1068-9265
VL - 31
SP - 753
EP - 761
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 2
ER -